當前位置：首頁 SCI期刊 SCIE期刊醫學中科院1區 JCRQ1 期刊介紹(非官網)

Journal Of Medicinal ChemistrySCIE

國際簡稱：J. Med. Chem. 參考譯名：藥物化學雜志

中科院分區
1區
CiteScore分區
Q1
JCR分區
Q1

基本信息：: ISSN：0022-2623; E-ISSN：1520-4804; 是否OA：開放; 是否預警：否; TOP期刊：是

出版信息：: 出版地區：UNITED STATES; 出版商：American Chemical Society; 出版語言：English; 出版周期：Biweekly; 出版年份：1959; 研究方向：醫學-醫藥化學

評價信息：: 影響因子：6.8; H-index：240; CiteScore指數：12.8; SJR指數：1.986; SNIP指數：1.594

發文數據：: Gold OA文章占比：13.77%; 研究類文章占比：98.81%; 年發文量：922; 自引率：0.1095...; 開源占比：0.099; 出版撤稿占比：0.0011...; 出版國人文章占比：0.14; OA被引用占比：0.0691...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數據中科院SCI分區 JCR分區發文數據常見問題

英文簡介Journal Of Medicinal Chemistry期刊介紹

The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.

Some specific areas that are appropriate include the following:

* Design, synthesis, and biological evaluation of novel biologically active compounds, diagnostic agents, or labeled ligands employed as pharmacological tools.

* Molecular modifications of reported series that lead to a significantly improved understanding of their structure-activity relationships (SAR). Routine extensions of existing series that do not utilize novel chemical or biological approaches or do not add significantly to a basic understanding of the SAR of the series will normally not be accepted for publication.

*Structural biological studies (X-ray, NMR, etc.) of relevant ligands and targets with the aim of investigating molecular recognition processes in the action of biologically active compounds.

* Molecular biological studies (e.g., site-directed mutagenesis) of macromolecular targets that lead to an improved understanding of molecular recognition.

*Computational studies that provide fresh insight into the SAR of compound series that are of current general interest or analysis of other available data that subsequently advance medicinal chemistry knowledge.

* Substantially novel computational chemistry methods with demonstrated value for the identification, optimization, or target interaction analysis of bioactive molecules.

* Effect of molecular structure on the distribution, pharmacokinetics, and metabolic transformation of biologically active compounds. This may include design, synthesis, and evaluation of novel types of prodrugs.

* Novel methodology with broad application to medicinal chemistry, but only if the methods have been tested on relevant molecules.

期刊簡介Journal Of Medicinal Chemistry期刊介紹

《Journal Of Medicinal Chemistry》自1959出版以來，是一本醫學優秀雜志。致力于發表原創科學研究結果，并為醫學各個領域的原創研究提供一個展示平臺，以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數據庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間：約2.1個月
國際TOP期刊
醫學
CHEMISTRY, MEDICINAL
SCIE
中科院1區
非預警

Cite Score數據（2024年最新版）Journal Of Medicinal Chemistry Cite Score數據

CiteScore：12.8
SJR：1.986
SNIP：1.594

學科類別	分區	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Drug Discovery	Q1	13 / 157	92%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Molecular Medicine	Q1	24 / 178	86%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎，針對的是前四年發表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區Journal Of Medicinal Chemistry 中科院分區

中科院 2023年12月升級版 綜述期刊：否 Top期刊：是

大類學科	分區	小類學科	分區
醫學	1區	CHEMISTRY, MEDICINAL 藥物化學	1區

中科院分區表 是以客觀數據為基礎，運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據，得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次，類似于“優、良、及格”等。最開始，這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

JCR分區Journal Of Medicinal Chemistry JCR分區

2023-2024 年最新版

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：CHEMISTRY, MEDICINAL	SCIE	Q1	4 / 72	95.1%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：CHEMISTRY, MEDICINAL	SCIE	Q1	1 / 72	99.31%

JCR分區的優勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區，這樣讀者可以根據自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發文數據

2023-2024 年國家/地區發文量統計

國家/地區數量
USA1072
CHINA MAINLAND529
GERMANY (FED REP GER)292
England275
Italy188
France145
Switzerland116
Spain115
Australia100
Canada97

本刊中國學者近年發表論文

1、Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small- cell Lung Cancer
Author: Pei, Junping; Wang, Guan; Wang, Aoxue; Wu, Chengyong; Pan, Xiaoli; Shuai, Wen; Bu, Faqian; Zhu, Yumeng; Wang, Yuxi; Ouyang, Liang; Li, Weimin

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. , Issue , pp. -. DOI: 10.1021/acs.jmedchem.3c00027
2、Discovery of Pyridinone Derivatives as Potent, Selective, and Orally Bioavailable Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Author: Zhu, Chenyu; Ze, Shuyin; Zhou, Ronghui; Yang, Xinyu; Wang, Haojie; Chai, Xiaolei; Fang, Meimiao; Liu, Mingyao; Wang, Yonghui; Lu, Weiqiang; Xie, Qiong

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4734-4754. DOI: 10.1021/acs.jmedchem.2c018604734J
3、Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway
Author: Zhang, Xinqi; Han, Qianyu; Hou, Ruilin; Xu, Lijuan; Zhang, Wannian; Xing, Chengguo; Xue, Lei; Zhuang, Chunlin

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 5261-5278. DOI: 10.1021/acs.jmedchem.3c00197
4、Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives
Author: Xie, Yuting; Yue, Lin; Shi, Yaojie; Su, Xingping; Gan, Cailing; Liu, Hongyao; Xue, Taixiong; Ye, Tinghong

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4342-4360. DOI: 10.1021/acs.jmedchem.2c01753
5、Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling
Author: Luo, Guangmei; Wang, Bingrui; Hou, Qiangqiang; Wu, Xiaoxing

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4324-4341. DOI: 10.1021/acs.jmedchem.2c01729
6、Unsymmetrical Phosphodiesters as GPR84 Antagonists with High Blood Exposure for the Treatment of Lung Inflammation
Author: Li, Shao-Xian; Wang, Si-Wei; Chen, Lin-Hai; Zhang, Qing; Lu, Dan; Chen, Jing; Fang, You-Chen; Gu, Min; Xie, Xin; Nan, Fa-Jun

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 8, pp. 5820-5838. DOI: 10.1021/acs.jmedchem.3c00053
7、Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1
Author: Gallego, Rebecca A.; Bernier, Louise; Chen, Hui; Cho-Schultz, Sujin; Chung, Loanne; Collins, Michael; Del Bel, Matthew; Elleraas, Jeff; Jones, Cinthia Costa; Cronin, Ciaran N.; Edwards, Martin; Fang, Xu; Fisher, Timothy; He, Mingying; Hoffman, Jacqui; Huo, Ruiduan; Jalaie, Mehran; Johnson, Eric; Johnson, Ted W.; Kania, Robert S.; Kraus, Manfred; Lafontaine, Jennifer; Le, Phuong; Liu, Tongnan; Maestre, Michael; Matthews, Jean; McTigue, Michele; Miller, Nichol; Mu, Qiming; Qin, Xulong; Ren, Shijian; Richardson, Paul; Rohner, Allison; Sach, Neal; Shao, Li; Smith, Graham; Su, Ruirui; Sun, Bin; Timofeevski, Sergei; Tran, Phuong; Wang, Shuiwang; Wang, Wei; Zhou, Ru; Zhu, Jinjiang; Nair, Sajiv K.

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. 66, Issue 7, pp. 4888-4909. DOI: 10.1021/acs.jmedchem.2c02038
8、Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers
Author: Qiu, Qianqian; Chi, Fanglian; Zhou, Daoguang; Xie, Zhancheng; Liu, Yunxiao; Wu, Hanyu; Yin, Ziyu; Shi, Wei; Qian, Hai

Journal: JOURNAL OF MEDICINAL CHEMISTRY. 2023; Vol. , Issue , pp. -. DOI: 10.1021/acs.jmedchem.3c00036